ERBB3 and melanoma: With qCLASH, we could identify predicted (miR-34a/AXL-3′UTR) and non-predicted miRNA–mRNA interactions (miR-34a/CD68-CDS) (Figure 9) as well as miRNA interactions with several receptor tyrosine kinases (RTKs) such as ERBB3 and AXL (Figure 7 and Figure 9), which have been shown to be upregulated in response to drug treatment and the subsequent development of drug resistance in melanoma cells and patients [43,44,45].